News
In vivo confocal microscopy (IVCM) is able to demonstrate the characteristic corneal and conjunctival ... useful in the follow-up of filtering blebs after trabeculectomy.
today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...
Design Therapeutics, Inc., a biotechnology company focused on treatments for genetic diseases, announced it will provide an update on its DT-168 program for Fuchs endothelial corneal dystrophy ...
"Alcon is dedicated to developing and delivering innovative treatments for global unmet needs in eye care, including vision-threatening corneal endothelial disease, which affects millions of ...
Taken together, IVCM will continue to gain importance in laboratory settings and clinical applications to evaluate the anatomy and pathology not only of the cornea and conjunctiva, but of the ...
In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...
into Phase 3 for corneal edema secondary to corneal endothelial disease during the second half of 2025. Aurion will have access to the broader R&D, regulatory, medical ophthalmic and commercial ...
DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results